{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:45Z","timestamp":1740148245995,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T00:00:00Z","timestamp":1502064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12094-017-1726-y","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T07:21:32Z","timestamp":1502090492000},"page":"392-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2771-4049","authenticated-orcid":false,"given":"I.","family":"Henr\u00edquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez-Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cassinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gonzalez San Segundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Unda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"L\u00f3pez-Torrecilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1726_CR2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1726_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bju.13059","volume":"117","author":"M Hemelrijck Van","year":"2016","unstructured":"Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507\u201314.","journal-title":"BJU Int"},{"issue":"11","key":"1726_CR4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2012.11504.x","volume":"110","author":"JM C\u00f3zar","year":"2012","unstructured":"C\u00f3zar JM, Mi\u00f1ana B, Gomez Veiga F, Rodr\u00edguez Antol\u00edn A, Villavicencio H, et al. Prostate cancer incidence and newly diagnosed patients profile in Spain in 2010. BJU Int. 2012;110(11):701\u20136.","journal-title":"BJU Int"},{"issue":"13","key":"1726_CR5","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.25900","volume":"117","author":"SA Boorjian","year":"2011","unstructured":"Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883\u201391.","journal-title":"Cancer"},{"issue":"3","key":"1726_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2011.11.043","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012;61(3):584\u201392.","journal-title":"Eur Urol"},{"issue":"1","key":"1726_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","volume":"67","author":"S Joniau","year":"2015","unstructured":"Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol. 2015;67(1):157\u201364.","journal-title":"Eur Urol"},{"issue":"1","key":"1726_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR, D\u2019Amico AV, Davis BJ, Eastham JA, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Prostate Cancer. Version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19\u201330.","journal-title":"J Natl Compr Canc Netw"},{"key":"1726_CR9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2016","unstructured":"Mottet N, BellmuntJ Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016;71:618\u201329.","journal-title":"Eur Urol"},{"issue":"10","key":"1726_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.acuro.2012.06.004","volume":"36","author":"JM C\u00f3zar","year":"2012","unstructured":"C\u00f3zar JM, Solsona E, Morote J, Mi\u00f1ana B, Maroto JP, Gonz\u00e1lez Del Alba A, et al. Recomendaciones sobre el manejo de controversias en c\u00e1ncer de pr\u00f3stata avanzado resistente a la castraci\u00f3n. Actas Urol Esp. 2012;36(10):569\u201377.","journal-title":"Actas Urol Esp"},{"key":"1726_CR11","unstructured":"Thompson I, Brantley Thrasher J, Aus G, Burnett AL, Canby-Hagino ED, et al. Guideline for the management of clinically localized prostate cancer. AUA Prostate Cancer Guideline. Version 1. 2016. (AUA guidelines\u00ae). http:\/\/www.auanet.org\/education\/guidelines\/ . Accessed Oct 2016."},{"key":"1726_CR12","unstructured":"American Society for Radiation Oncology (ASTRO) guidelines on prostate cancer. Prostate Cancer Guideline. http:\/\/www.astro.org . Accessed Nov 2016."},{"key":"1726_CR13","doi-asserted-by":"crossref","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, GrossT, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Ann Oncol 2015. http:\/\/uroweb.org\/guideline\/prostate-cancer\/ (Eur Urol 2016).","DOI":"10.1016\/j.eururo.2016.08.002"},{"key":"1726_CR14","unstructured":"American Society of Clinical Oncology (ASCO) guidelines on prostata cancer. Prostate cancer guidelines. http:\/\/www.asco.org . Accessed Nov 2016."},{"issue":"Suppl 5","key":"1726_CR15","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1093\/annonc\/mdv222","volume":"5","author":"C Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;5(Suppl 5):S69\u201377. doi: 10.1093\/annonc\/mdv222 .","journal-title":"Ann Oncol"},{"key":"1726_CR16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1726_CR17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68\u00a0Ga-prostate-specific membrane antigen positron emission tomography in Advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol"},{"key":"1726_CR18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","volume":"70","author":"SD Fossa","year":"2016","unstructured":"Fossa SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten and 15\u00a0yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group 7. Eur Urol. 2016;70:684\u201391.","journal-title":"Eur Urol"},{"key":"1726_CR19","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","volume":"33","author":"MD Mason","year":"2015","unstructured":"Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the Intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33:2143\u201350.","journal-title":"J Clin Oncol"},{"key":"1726_CR20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","volume":"62","author":"N Mottet","year":"2012","unstructured":"Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012;62:213\u20139.","journal-title":"Eur Urol"},{"key":"1726_CR21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066\u201373.","journal-title":"Lancet Oncol"},{"key":"1726_CR22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","volume":"16","author":"A Zapatero","year":"2015","unstructured":"Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez SanSegundo C, Cabeza Rodr\u00edguez MA, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:320\u20137.","journal-title":"Lancet Oncol"},{"key":"1726_CR23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2013.394","volume":"109","author":"A Creak","year":"2013","unstructured":"Creak A, Hall E, Horwich A, Eeles R, Khoo V, Huddart R, et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. Br J Cancer. 2013;109:651\u20137.","journal-title":"Br J Cancer"},{"key":"1726_CR24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1726_CR25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","volume":"28","author":"AL Zietman","year":"2010","unstructured":"Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106\u201311.","journal-title":"J Clin Oncol"},{"key":"1726_CR26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","volume":"110","author":"WD Heemsbergen","year":"2014","unstructured":"Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104\u20139.","journal-title":"Radiother Oncol"},{"key":"1726_CR27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","volume":"80","author":"V Beckendorf","year":"2011","unstructured":"Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70\u00a0Gy versus 80\u00a0Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80:1056\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1726_CR28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","volume":"15","author":"DP Dearnaley","year":"2014","unstructured":"Dearnaley DP, Jovic G, Syindikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15:464\u201373.","journal-title":"Lancet Oncol"},{"key":"1726_CR29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","volume":"115","author":"NG Zaorsky","year":"2015","unstructured":"Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015;115:295\u2013300.","journal-title":"Radiother Oncol"},{"issue":"11","key":"1726_CR30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1464-410X.2012.11372.x","volume":"110","author":"CR Mitchell","year":"2012","unstructured":"Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709\u201313.","journal-title":"BJU Int"},{"issue":"4","key":"1726_CR31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2012.08.054","volume":"63","author":"A Briganti","year":"2013","unstructured":"Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT), et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013;63(4):693\u2013701.","journal-title":"Eur Urol"},{"key":"1726_CR32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10354-015-0389-y","volume":"165","author":"C Lanchon","year":"2015","unstructured":"Lanchon C, Shariat SF, Roupret M. The role for surgery in high-risk prostate cancer. Wien MEd Wocheschr. 2015;165:395\u2013400.","journal-title":"Wien MEd Wocheschr"},{"key":"1726_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1464-410X.2007.07269.x","volume":"101","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8\u201310 cancers. BJU Int. 2008;101:299\u2013304.","journal-title":"BJU Int"},{"key":"1726_CR34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5114\/jcb.2014.45759","volume":"6","author":"GC Morton","year":"2014","unstructured":"Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy. 2014;6:323\u201330.","journal-title":"J Contemp Brachytherapy"},{"key":"1726_CR35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2009.10.035","volume":"79","author":"AA Martinez","year":"2011","unstructured":"Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, et al. Dose escalation improves cancer-related events at 10\u00a0years for intermediate- and high-risk prostate cancer patients treated with hypofractionationated high-dose-rate boost and external beam radiotherapy. Int J Rad Oncol Biol Phys. 2011;79:363\u201370.","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"1726_CR36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2014.07.013","volume":"112","author":"A Boladeras","year":"2014","unstructured":"Boladeras A, Santorsa L, Gutierrez C, Martinez E, Pera J, Pino F, et al. External radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. Radiother Oncol. 2014;112:227\u201332.","journal-title":"Radiother Oncol"},{"key":"1726_CR37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","volume":"23","author":"JR Sathya","year":"2005","unstructured":"Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192\u20139.","journal-title":"J Clin Oncol"},{"key":"1726_CR38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","volume":"103","author":"PJ Hoskin","year":"2012","unstructured":"Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103:217\u201322.","journal-title":"Radiother Oncol"},{"key":"1726_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.026","author":"WJ Morris","year":"2016","unstructured":"Morris WJ, Tydesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. ASCENDE-RT: an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2016;. doi: 10.1016\/j.ijrobp.2016.11.026 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1726_CR40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamasurg.2014.31","volume":"149","author":"JK Parsons","year":"2014","unstructured":"Parsons JK, Messer K, Palazzi K, Stroup S, Chang S. Diffusion of surgical innovations, patient safety, and minimally invasive radical prostatectomy. JAMA Surg. 2014;149(8):845\u201351.","journal-title":"JAMA Surg"},{"key":"1726_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2490-14-25","volume":"14","author":"S Carlsson","year":"2014","unstructured":"Carlsson S, Berglund A, Sjoberg D, Khatami A, Stranne J, Bergdahl S, et al. Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol. 2014;14:25.","journal-title":"BMC Urol"},{"key":"1726_CR42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17:243\u201356.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1726_CR43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2010.10.045","volume":"59","author":"A Vickers","year":"2011","unstructured":"Vickers A, Savage C, Bianco F, Mulhall J, Sandhu J, Guillonneau B, et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol. 2011;59(3):317\u201322.","journal-title":"Eur Urol"},{"issue":"6","key":"1726_CR44","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.eururo.2014.02.009","volume":"65","author":"DC Miller","year":"2014","unstructured":"Miller DC, Birkmeyer JD. Moving beyond the headlines: improving the technical quality of radical prostatectomy. Eur Urol. 2014;65(6):1020\u20132.","journal-title":"Eur Urol"},{"issue":"4","key":"1726_CR45","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.urology.2015.01.006","volume":"85","author":"EH Wang","year":"2015","unstructured":"Wang EH, Yu JB, Gross CP, Abouassaly R, Cherullo EE, Smaldone MC, et al. Association between surgeon and hospital characteristics and lymph node counts from radical prostatectomy and pelvic lymph node dissection. Urology. 2015;85(4):890\u20135.","journal-title":"Urology"},{"issue":"3","key":"1726_CR46","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.juro.2008.05.010","volume":"180","author":"TJ Wilt","year":"2008","unstructured":"Wilt TJ, Shamliyan TA, Taylor BC, MacDonald R, Kane RL. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol. 2008;180(3):820\u20138.","journal-title":"J Urol"},{"issue":"5","key":"1726_CR47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.eururo.2013.04.012","volume":"64","author":"QD Trinh","year":"2013","unstructured":"Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, Hu JC, Shariat SF, et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol. 2013;64(5):786\u201398.","journal-title":"Eur Urol"},{"issue":"3","key":"1726_CR48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-410X.2012.11671.x","volume":"112","author":"CG Eden","year":"2013","unstructured":"Eden CG, Zacharakis E, Bott S. The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer: implications for compliance with existing guidelines. BJU Int. 2013;112(3):346\u201354.","journal-title":"BJU Int"},{"issue":"1","key":"1726_CR49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2015.02.028","volume":"68","author":"P Cathcart","year":"2015","unstructured":"Cathcart P, Sridhara A, Ramachandran N, Briggs T, Nathan S, Kelly J. Achieving quality assurance of prostate cancer surgery during reorganisation of cancer services. Eur Urol. 2015;68(1):22\u20139.","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1726-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T21:01:25Z","timestamp":1659301285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1726-y","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2017,8,7]]}}}